At veriNOS pharmaceuticals GmbH, we focus on the clinical development of a drug that specifically inhibits a defined cascade that is relevant and common in different disease settings.

The activation of iNOS with subsequent excessive production of cell damaging radicals and massive excitotoxic glutamate increase is of crucial importance in all of our indications of interest.

Our goal of using Ronopterin is to selectively inhibit upregulated iNOS to reduce radicals and excitotoxic glutamate levels.

Our management team consists of experienced biopharma executives with complementary backgrounds, including corporate governance, finance, medicine and science.



Clinical Trials

Pharmaceutical

Life Sciences

Biotechnology

veriNOS pharmaceuticals

veriNOS pharmaceuticals' headquarters in Wuerzburg, Germany

Christian Wandersee

This department provides strategic direction and oversight for the organization, guiding its mission and vision.

veriNOS pharmaceuticals

Org chart

Teams

Executive Leadership

Offices

veriNOS pharmaceuticals

Org chart

Teams

Executive Leadership

Offices

Related companies